DFC_MK-7339-006

A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer

In male and female participants with Stage IV nonsquamous non–small-cell lung cancer
(NSCLC) with stable disease (SD), partial response (PR), or complete response (CR)
following induction treatment with pembrolizumab combined with pemetrexed and platinum
(carboplatin or cisplatin)
Phase III
NCT03976323
Cancer
Lung
Raul Mena, M.D.
Sarah Correa, RN
  • John Wayne Cancer Institute (JWCI)
  • Providence Los Angeles Research Center